- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events
XARELTO® Has the Broadest Indication Profile of Any New Oral Anticoagulant
New One-Year Phase 3 Study Results Show Anti-Tnf SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis
Data Demonstrate Remission and Mucosal Healing with SIMPONI Maintenance Therapy
Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA® Treatment
STELARA Phase 2b Crohn’s Disease Study Published in The New England Journal of Medicine
First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
Canagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study
Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
Orally Administered Investigational Therapy Expands Global Immunology Portfolio
New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
New Analyses from Phase 3 COU-AA-302 Study Also Suggest Radiographic Progression-Free Survival Positively Associated with Overall Survival
Janssen Connected Health Challenge Europe 2012 Launching To Spur Healthcare Innovation
Janssen Connected Health Challenge seeks transformational care ideas and offers awards totalling €30,000 to develop winning solutions